John Rim: “This Year Will Be the Starting Point for a New Leap Forward”
John Rim, CEO of Samsung Biologics, speaks during the company’s 14th regular shareholders’ meeting held at Songdo Convensia in Incheon on the morning of the 14th. [Provided by Samsung Biologics]
Seoul, Herald Economy (by reporter Choi Eun-ji) – Samsung Biologics has restructured its board by appointing Vice President Yoo Seung-ho as an internal director and former Presidential Office Policy Director Lee Ho-seung as an external director.
Samsung Biologics held its 14th regular shareholders’ meeting on the 14th at Songdo Convensia in Incheon Songdo International City, where they resolved and approved these director appointments.
Lee Chang-woo, professor emeritus at Seoul National University, who has served as an external director and audit committee chairman for the past three years, was reappointed.
As a result, the internal directors were organized as John Rim, Yoo Seung-ho, and Noh Kyun, EPCV center head. The external directors include Lee Ho-seung, Kim Eunice-Gyeonghee, a member of the ESG Standards Committee of the Korea ESG Standards Institute, Lee Chang-woo, and Seo Seung-hwan, president of Yonsei University.
Approximately 1,700 shareholders attended the shareholders’ meeting, which lasted about 30 minutes from 9 a.m., both on-site and online. Samsung Biologics enabled online voting from March 4 to 13 to allow shareholders who could not attend in person to exercise their voting rights.
A total of six agenda items were submitted and approved at the shareholders’ meeting, including the approval of financial statements, amendments to the articles of incorporation, and the appointment of internal and external directors and audit committee members.
John Rim, CEO of Samsung Biologics, stated, “We intend to make this year the starting point for a new leap forward,” adding that “the fifth plant, which will usher in the era of the second Bio Campus, is set to be completed in April.”
He further stated, “We will continue our efforts to expand our portfolio and global presence.”
He also stated, “All achievements of Samsung Biologics have been possible because of the support and trust of our shareholders,” and requested “continued interest and support as Samsung Biologics grows into a global top-tier bio company.”